Delivery Order SPE2DR25D3010-SPE2DR26F88LP
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on January 5, 2026, for the supply of Xcopri 100 mg tablets (30-count units) under a firm fixed-price contract valued at $3,607.92, with completion expected by January 6, 2026. This is a competitive award with no set-aside designation, performed at AmerisourceBergen's Conshohocken, Pennsylvania facility. The delivery order is issued under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a delivery order valued at $2,503.97 to AmerisourceBergen Drug Corp for Xcopri 150 mg tablets (30-count units) on August 14, 2025, with completion targeted for August 15, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's Conshohocken, Pennsylvania facility. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical vendor for federal medical...
- The Defense Logistics Agency awarded a delivery order valued at $5,570.08 to AmerisourceBergen Drug Corp for the supply of Xcopri 50 mg tablets (30-count) on January 9, 2026, with an ultimate completion date of January 12, 2026. This is a firm fixed-price, non-set-aside contract performed at the vendor's location in Conshohocken, Pennsylvania. The award represents a task order under AmerisourceBergen's parent company Cencora, Inc.'s larger Indefinite Delivery Contract with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $1,801.47 on December 18, 2025, for the supply of Xcopri 150 mg tablets (30-count packaging). This is a firm fixed-price delivery order with an ultimate completion date of December 19, 2025, and represents a non-set-aside competitive award. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $1,178.96 to AmerisourceBergen Drug Corp for 30 tablets of Xcopri 150 mg, with an ultimate completion date of September 2, 2025. This is a firm fixed price delivery order with no set-aside designation, issued competitively to the prime contractor. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a $1,184.59 delivery order to AmerisourceBergen Drug Corp on November 14, 2025, for the supply of Xcopri 200 mg tablets (30-count package). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of November 17, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a single transaction under...
- The Defense Logistics Agency awarded a delivery order valued at $2,794.23 to AmerisourceBergen Drug Corp for 30-tablet units of Xcopri 150 mg tablets, with a completion date of September 11, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $5,136.21 to AmerisourceBergen Drug Corp for the supply of Xcopri 50 mg tablets (30-count package). This competitive, firm fixed-price delivery order was issued on January 12, 2026, with an ultimate completion date of January 13, 2026. The award was made to the Conshohocken, Pennsylvania-based pharmaceutical distributor, which serves as a critical vendor for federal medical procurement needs across military and veteran healthcare...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Xcopri 100 mg tablets (30-count package) valued at $1,218.35 under a firm fixed-price contract type. The award was made on November 24, 2025, with an ultimate completion date of November 25, 2025, and represents a non-competitive, non-set-aside procurement. This delivery order is a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical, designated...
- The Defense Logistics Agency awarded a delivery order valued at $3,652.69 to AmerisourceBergen Drug Corp for 30-tablet units of Xcopri 200 mg tablets, with performance completion targeted for August 20, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. The pharmaceutical product will be delivered to AmerisourceBergen's corporate...
- SPE2DR25D3010Indefinite Delivery Contract
- SPE2DR25D3010-SPE2DR26F88LPDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,944.40 to AmerisourceBergen Drug Corp for the supply of Xcopri 50 mg tablets (30-count packaging) on January 12, 2026, with an ultimate completion date of January 13, 2026. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a subsidiary of parent company Cencora, Inc., is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement needs across military and veteran healthcare systems. This delivery order is issued under AmerisourceBergen's Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at up to $999,999,999.00 through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs worldwide. The IDC encompasses a broad range of pharmaceutical products and medical supplies, including specialty medications, brand-name and generic drugs, vaccines, and specialized medical commodities across multiple therapeutic domains. Xcopri, a seizure medication used in neurological treatment, represents one component of the extensive pharmaceutical portfolio delivered through this prime contract vehicle to support Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.9k | 1/11/26 |